however, NICE has indicated that semaglutide may remain the preferred first-line GLP-1 agent in many formularies, owing to cost-effectiveness thresholds 3,16
Giaconi said, The VA in Los Angeles recently made a GLP-1 formulary switch to semaglutide, which is great for glycemic control, but it worsens existing diabetic retinopathy
The starting dose is 0.25 mg per week
If fatigue persists beyond four to six weeks, discuss with your provider
At this concentration, the molecule is absolutely present in your system and active at GLP-1 receptors
To strengthen your claim, be prepared to provide: Prescription records showing use of Ozempic, Wegovy, or Mounjaro Medical records indicating diagnosis and treatment of GI issues Doctors notes on symptom progression Emergency room visit records Test results, including gastric emptying studies Out-of-pocket costs and lost income documentation A personal journal detailing how the condition has impacted your daily life Morgan & Morgan can help gather this information and present it effectively